什么时候考虑冠状动脉复血管化治疗稳定冠状动脉疾病
Andrew M Cheng1, Jacob A Doll1
1Division of Cardiology, Department of Medicine, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA; Section of Cardiology, VA Puget Sound Health Care System, 1660 South Columbian Way S111-CARDIO, Seattle, WA 98108, USA.
The Medical clinics of North America
|March 28, 2024
概括
重血管化有助于慢性冠状动脉疾病患者,但决策需要平衡好处与风险. 指南提供了一个框架,但个体患者的因素是最佳治疗的关键.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 临床医学 临床医学
背景情况:
- 重血管化是慢性冠状动脉疾病的一种成熟治疗方法.
- 对于许多患者的最佳再血管化策略,仍存在不确定性.
- 冠状动脉旁路移植在严重的冠状动脉疾病中具有特定的征兆.
研究的目的:
- 探索慢性冠状动脉疾病中复杂的重血管化决策.
- 突出需要个性化治疗方法的需要.
- 讨论重新血管化的潜在好处和风险之间的平衡.
主要方法:
- 审查现有的随机试验和临床指南.
- 对影响重血管化决定的因素的分析.
- 考虑患者特定的解剖学,临床状况和偏好.
主要成果:
- 冠状动脉旁路移植是对左主狭窄或严重的多血管疾病 (射出分数≤35%) 的I类指示.
- 对于其他患者来说,必须权衡重血管化的好处 (缓解症状,减少心脏病发作/死亡) 与风险和成本.
- 个体患者的因素显著影响决策过程.
结论:
- 重血管化的决定需要仔细考虑,而不仅仅是一般指导方针.
- 对冠状动脉解剖,临床因素和患者偏好的个性化评估至关重要.
- 优化慢性冠状动脉疾病的治疗涉及到一个细微的方法来恢复血管.
相关概念视频
01:17Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
500
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
500